Vonicog_alfa
Vonicog alfa
Pharmaceutical drug
Vonicog alfa, sold under the brand names Vonvendi and Veyvondi, is a medication used to control bleeding in adults with von Willebrand disease (an inherited bleeding disorder).[6][5][7][8] It is a recombinant von Willebrand factor.[6][5]
The most common adverse reactions are generalized itching, vomiting, nausea, dizziness, and vertigo.[6]
Vonicog alfa should not be used in the treatment of Hemophilia A.[5]
In the UK it is available only via a named patient access program.[9]
Vonicog alfa was approved for medical use in the United States in December 2015, in the European Union in August 2018, and in Australia in April 2020.[4][6][5][10] It was granted orphan drug designations in both the United States and the European Union.[5][1]